The 5' binding MID domain of human Argonaute2 tolerates chemically modified nucleotide analogues.

@article{Deleavey2013The5B,
  title={The 5' binding MID domain of human Argonaute2 tolerates chemically modified nucleotide analogues.},
  author={Glen F. Deleavey and Filipp Frank and Melanie R. Hassler and Simon P. Wisnovsky and Bhushan Nagar and Masad J Damha},
  journal={Nucleic acid therapeutics},
  year={2013},
  volume={23 1},
  pages={
          81-7
        }
}
Small interfering RNAs (siRNAs) can trigger potent gene silencing through the RNA interference (RNAi) pathway. The RNA-induced silencing complex (RISC) is key to this targeted mRNA degradation, and the human Argonaute2 (hAGO2) endonuclease component of RISC is responsible for the actual mRNA cleavage event. During RNAi, hAGO2 becomes loaded with the siRNA guide strand, making several key nucleic acid-enzyme interactions. Chemically modified siRNAs are now widely used in place of natural double… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

The structure of human argonaute-2 in complex with miR-20a

E. ELKAYAM, KUHN, +5 authors L. JOSHUA-TOR
  • Cell 150,
  • 2012
VIEW 2 EXCERPTS

Binding and cleavage specificities of human Argonaute2.

  • The Journal of biological chemistry
  • 2009
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…